Dr. Ruchika Talwar

There's a lot of nuance here.

Yeah.

And just for completeness sake, I mean, you mentioned Decipher.

You mentioned you referenced Arterra AI prostate analyses.

What other commercially available products are out there?

Yeah.

You know, we've talked a lot about the specific cancer biology, the clinical data we have available, but let's now talk about what I think is actually the most important aspect of this clinical scenario, and that is patient counseling, because I think it has a profound impact on

the decision that the patient makes.

Ultimately, it's all shared decision making.

There is no right or wrong answer here.

And active surveillance is an equally reasonable option as compared to active treatment.

So tell me, how do you start out by framing this conversation in a patient who may be pretty anxious, actually?

Like it's another day in clinic for you and I, but this may be the worst day of this patient's life.

Yeah, I totally agree.

I use that strategy too.

And I'll say things like, you know, this is not a commitment.

The nice thing about choosing active surveillance is we can change our strategy.

If you go home later today and you say, you know what, I feel really uncomfortable with this.

I want to proceed with active treatment.

No problem.